Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: Comparative risk assessment results from a pooled analysis

Transplantation

Volumn 96, Issue 12, 2013, Pages 1073-1081

  Melancon, Keith ^a   Mulgaonkar, Shamkant P ^b   Delcoro, Carlos ^c   Wiland, Anne ^d   McCague, Kevin ^d   Shihab, Fuad S ^e  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Hospital Auxilio Mutuo   (Puerto Rico)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Everolimus; Mycophenolate; Renal transplantation

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; END STAGE RENAL DISEASE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; FEVER; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 84891614227     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a486f5     Document Type: Article

References (26)

1. Doshi MD, Garg N, Reese PP, et al. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation 2011; 91: 666.
2. Fan PY, Ashby VB, Fuller DS, et al. Access and outcomes among minority transplant patients, 1999Y2008, with a focus on determinants of kidney graft survival. Am J Transplant 2010; 10: 1090.
3. Luan FL, Kommareddi M, Cibrik DM, et al. Influence of recipient race on the outcome of simultaneous pancreas and kidney transplantation. Am J Transplant 2010; 10: 2074.
4. Patel SJ, Duhart BT Jr, Krauss AG, et al. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Transplantation 2008; 86: 313.
5. Ng FL, Holt DW, Chang RWS, et al. Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dialysis Transplant 2010; 25: 628.
6. Padiyar A, Augustine JJ, Bodziak KA, et al. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant Proc 2010; 42: 1643.
7. Yeates K, Wiebe N, Gill J, et al. Similar outcomes among black and white renal allograft recipients. J Am Soc Nephrol 2009; 20: 172.
8. Pallet N, Thervet E, Alberti C, et al. Kidney transplant in black recipients: are African Europeans different from African Americans?. Am J Transplant 2005; 5: 2682.
9. Rudge C, Johnson R, Fuggle SV, et al. Renal transplantation in the United Kingdom for patients from ethnic minorities. Transplantation 2007; 83: 1169.
10. http://optn.transplant.hrsa.gov/latestData/rptStrat.asp. OPTN data. Accessed July 20, 2012.
11. Silva HT Jr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
12. Santos SM, Carlos CM, Cabanayan-Casasola CB, et al. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year singlecenter experience. Transplant Proc 2012; 44: 154.
13. V?́tko S ?, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
14. Lorber MI, Mulgaonkar S, Butt KMH, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
15. Vitko S ?, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
16. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
17. Bertoni E, Larti A, Rosso G, et al. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol 2011; 24: 613.
18. Cibrik D, Arcona S, Vasquez E, et al. Long-term experience with everolimus in kidney transplantation in the United States. Transplant Proc 2011; 43: 2562.
19. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2010; 10: 1.
20. Lodhi SA, Meier-Kriesche HU. Kidney allograft survival: the long and short of it. Nephrol Dialysis Transplant 2011; 26: 15.
21. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
22. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
23. Campistol JM, de Fijter JW, Nashan B, et al. Everolimus and long-term outcomes in renal transplantation. Transplantation 2011; 92: S3.
24. Monaco AP, Morris PJ. Everolimus and long-term outcomes in renal transplantation: seeking an optimal strategy for immunosuppression. Transplantation 2011; 92: S1.
25. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
26. Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2012; 61: 57.